Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 2
March 19, 2012
- Nichi-Iko Definitely to Enter as Global Top-10 Generics Company within 4 Years: President Tamura
March 16, 2012
- Fuji-Keizai Predicts Japan’s Generics Market to Exceed ¥580 Billion in 2014
March 16, 2012
- All-Case PMS for Sutent Lifted: Pfizer
March 16, 2012
- Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
- Teva-Kowa, Taiyo, Nippon Kayaku Apply for Approval of Gran Biosimilar
March 15, 2012
- Shionogi Submits Clinical Trial Application in Europe for OncoTherapy’s Cancer Vaccine
March 15, 2012
- Nichi-Iko Makes Yakuhan Its Subsidiary, Acquiring 69% of Company’s Stock
March 15, 2012
- Qol to Appoint Daiichi Sankyo Espha Chairman as Managing Director
March 15, 2012
- Nichi-Iko Announces New Med-Term Management Plan, Targets ¥130 Billion Sales in Mar 2016
March 15, 2012
- Baxter Reports Temporary Suspension in Shipments of Albumin Products to Japan
March 15, 2012
- MR Survey Shows Number of Doctors Visited, Detailing Activity Downtrend
March 14, 2012
- Pharmacists Rate Pfizer Highly for Generic Selection: Survey
March 14, 2012
- Nihon Chouzai to Provide Generic Drug Information System to Pharmacies of Other Companies
March 14, 2012
- Astellas and UMN Announce Favorable Phase II Results for Influenza HA Vaccine
March 14, 2012
- Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
- MediciNova Obtains Notice of Patent Allowance for Ibudilast for Treatment of Chronic Neuropathic Pain
March 14, 2012
- Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
- Upcoming Reforms “Ideal” for Promoting Use of Generic Drugs: President Sawai of Sawai Pharm.
March 13, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…